These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
347 related articles for article (PubMed ID: 25283184)
1. Role of oral pre-exposure prophylaxis (PrEP) in current and future HIV prevention strategies. Burns DN; Grossman C; Turpin J; Elharrar V; Veronese F Curr HIV/AIDS Rep; 2014 Dec; 11(4):393-403. PubMed ID: 25283184 [TBL] [Abstract][Full Text] [Related]
2. Preexposure prophylaxis for HIV infection. Steinbrook R JAMA; 2012 Sep; 308(9):865-6. PubMed ID: 22820712 [No Abstract] [Full Text] [Related]
3. Ethical challenges of preexposure prophylaxis for HIV. Jay JS; Gostin LO JAMA; 2012 Sep; 308(9):867-8. PubMed ID: 22847147 [No Abstract] [Full Text] [Related]
4. From modeling to morals: imagining the future of HIV PREP in Lesotho. Kenworthy NJ; Bulled N Dev World Bioeth; 2013 Aug; 13(2):70-8. PubMed ID: 23800326 [TBL] [Abstract][Full Text] [Related]
5. I Am Men's Health: Generating Adherence to HIV Pre-Exposure Prophylaxis (PrEP) in Young Men of Color Who Have Sex with Men. Daughtridge GW; Conyngham SC; Ramirez N; Koenig HC J Int Assoc Provid AIDS Care; 2015; 14(2):103-7. PubMed ID: 25331226 [TBL] [Abstract][Full Text] [Related]
6. FDA paves the way for pre-exposure HIV prophylaxis. Holmes D Lancet; 2012 Jul; 380(9839):325. PubMed ID: 22852138 [No Abstract] [Full Text] [Related]
7. A polyvalent Clade B virus-like particle HIV vaccine combined with partially protective oral preexposure prophylaxis prevents simian-human immunodeficiency virus Infection in macaques and primes for virus-amplified immunity. Ross TM; Pereira LE; Luckay A; McNicholl JM; García-Lerma JG; Heneine W; Eugene HS; Pierce-Paul BR; Zhang J; Hendry RM; Smith JM AIDS Res Hum Retroviruses; 2014 Nov; 30(11):1072-81. PubMed ID: 24914761 [TBL] [Abstract][Full Text] [Related]
8. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial. Baeten JM; Donnell D; Mugo NR; Ndase P; Thomas KK; Campbell JD; Wangisi J; Tappero JW; Bukusi EA; Cohen CR; Katabira E; Ronald A; Tumwesigye E; Were E; Fife KH; Kiarie J; Farquhar C; John-Stewart G; Kidoguchi L; Coombs RW; Hendrix C; Marzinke MA; Frenkel L; Haberer JE; Bangsberg D; Celum C; Lancet Infect Dis; 2014 Nov; 14(11):1055-1064. PubMed ID: 25300863 [TBL] [Abstract][Full Text] [Related]
10. A perspective on progress and gaps in HIV prevention science. Kiser PF; Mesquita PM; Herold BC AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1373-8. PubMed ID: 22966871 [TBL] [Abstract][Full Text] [Related]
12. Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns. Tetteh RA; Yankey BA; Nartey ET; Lartey M; Leufkens HG; Dodoo AN Drug Saf; 2017 Apr; 40(4):273-283. PubMed ID: 28130774 [TBL] [Abstract][Full Text] [Related]
13. Are we prepped for preexposure prophylaxis (PrEP)? Provider opinions on the real-world use of PrEP in the United States and Canada. Karris MY; Beekmann SE; Mehta SR; Anderson CM; Polgreen PM Clin Infect Dis; 2014 Mar; 58(5):704-12. PubMed ID: 24319083 [TBL] [Abstract][Full Text] [Related]
14. Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force. Chou R; Evans C; Hoverman A; Sun C; Dana T; Bougatsos C; Grusing S; Korthuis PT JAMA; 2019 Jun; 321(22):2214-2230. PubMed ID: 31184746 [TBL] [Abstract][Full Text] [Related]
15. Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States. Adams JL; Shelley K; Nicol MR Pharmacotherapy; 2019 Apr; 39(4):486-500. PubMed ID: 30815960 [TBL] [Abstract][Full Text] [Related]
16. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges. Krakower DS; Mayer KH Drugs; 2015 Feb; 75(3):243-51. PubMed ID: 25673022 [TBL] [Abstract][Full Text] [Related]
17. Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012-2017. Sullivan PS; Giler RM; Mouhanna F; Pembleton ES; Guest JL; Jones J; Castel AD; Yeung H; Kramer M; McCallister S; Siegler AJ Ann Epidemiol; 2018 Dec; 28(12):833-840. PubMed ID: 30037634 [TBL] [Abstract][Full Text] [Related]
18. HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans. Spinner CD; Boesecke C; Zink A; Jessen H; Stellbrink HJ; Rockstroh JK; Esser S Infection; 2016 Apr; 44(2):151-8. PubMed ID: 26471511 [TBL] [Abstract][Full Text] [Related]
19. Uptake of PrEP for HIV slow among MSM. Kirby T; Thornber-Dunwell M Lancet; 2014 Feb; 383(9915):399-400. PubMed ID: 24494225 [No Abstract] [Full Text] [Related]
20. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial. Celum C; Morrow RA; Donnell D; Hong T; Hendrix CW; Thomas KK; Fife KH; Nakku-Joloba E; Mujugira A; Baeten JM; Ann Intern Med; 2014 Jul; 161(1):11-9. PubMed ID: 24979446 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]